🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› EU
Clinical trial register · European Union · CTIS

Recently authorised EU trials

The most recently authorised trials on the EU Clinical Trials Information System (CTIS), the single register for every trial run under the EU Clinical Trials Regulation (536/2014). CTIS holds a far larger historical archive than any one list can usefully show — this register states both numbers rather than picking one.

Download CSV
Source: EMA Clinical Trials Information System (CTIS). Showing the 2500 most recently authorised of 12445 total CTIS records — a stated recency window, not the full historical archive. Synced 20 Sep 2026, 03:17 UTC
2500
Shown in this register
most recently authorised
12,445
Total on CTIS
full historical archive
745
Phase III
within the shown window
Top member states
Spain 1023 France 890 Germany 861 Italy 742 Poland 581 Netherlands 524
Narrow the registerReset
Phase
Phase I 558 Phase I/II 214 Phase II 726 Phase III 745 Phase IV 257
Lead sponsor
AstraZeneca AB 60 Assistance Publique Hopitaux De Paris 49 Merck Sharp & Dohme LLC 48 Pfizer Inc. 45 Novo Nordisk A/S 42
Member state
Spain 1023 France 890 Germany 861 Italy 742 Poland 581 Netherlands 524 Belgium 426 Czechia 327
All 28 states
726 of 2500 shown studies
Download
Phase
Study
Lead sponsor
Area
Member states
Decision
Phase II
AN OPEN LABEL, SINGLE ARM, EXPLORATIVE TRIAL TO EVALUATE EFFICACY AND SAFETY OF BEROTRALSTAT IN PREVENTING ANGIOEDEMA ATTACKS IN SUBJECTS WITH ACQUIRED ANGIOEDEMA DUE TO C1 INHIBITOR DEFICIENCY (AAE)
2025-524747-13-00Acquired angioedema due to C1 inhibitor deficiency
Policlinico San Donato S.p.A.
Genetic Phenomena
Italy
12/08/2026
Phase II
A RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER, CLINICAL TRIAL OF COLCHICINE IN AMYOTROPHIC LATERAL SCLEROSIS (CO-ALS II)
2026-526460-20-00AMYOTROPHIC LATERAL SCLEROSIS
Azienda Ospedaliero Universitaria Di Modena
Musculoskeletal Diseases
Italy
12/08/2026
Phase II
A phase II, single arm two-phase, clinical study of individually adapted systemic radioligand therapy with 177Lu-PSMA I&T for patients with metastatic, castration-resistant prostate cancer
2026-527110-23-00Prostate cancer
Region Uppsala
Male Urogenital Diseases
Sweden
12/08/2026
Phase II
Evaluation of the efficacy, safety, and tolerability of lutetium-177-labeled PSMA ligand in patients with progression of adenoid cystic carcinoma originating from the salivary glands - an open, non-commercial clinical trial
2026-525776-26-00adenoid cystic carcinoma of the salivary glands
Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy
Otorhinolaryngologic Diseases
Poland
12/08/2026
Phase II
Valproic acid and lenvatinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma
2026-525733-24-00Recurrent and/or Metastatic Adenoid Cystic Carcinom
Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia
Neoplasms
Italy
11/08/2026
Phase II
J2S-MC-GZMT: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Brenipatide in the Treatment of Adult Participants with IBS-C
2025-524974-41-00Irritable Bowel Syndrome - Constipation
Eli Lilly & Co.
Digestive System Diseases
Belgium, Spain
11/08/2026
Phase II
SDH-FLUX - Development of a new biomarker for tumor development in patients with SDHx mutation by in vivo fluxomics
2023-506001-19-00paraganglioma or pheochromocytoma with surgical indication
Assistance Publique Hopitaux De Paris
Hormonal diseases
France
10/08/2026
Phase II
A Phase 2 Multicentric Randomized Double-Blinded Efficacy and Safety Clinical Trial Comparing Several Doses of Aganirsen Eye Drops Emulsion to Extend Intravitreal Aflibercept Treatment Interval in Wet Age-Related Macular Degeneration (wAMD) Patients - SKY2 Study
2026-526775-27-00Wet Age-Related Macular Degeneration (wAMD) Patients
Laboratoires Kol
Eye Diseases
France
10/08/2026
Phase II
Effects of a CB1 Antagonist/Reverse Agonist (Rimonabant) on Functional Recovery in Stroke Patients During Subacute Phase.
2025-521689-86-00Stroke
Sinfatin S.L.
Nervous System Diseases
Spain
10/08/2026
Phase II
A Phase 2, Multicenter, Open-Label Study of Zolacabtagene Autoleucel (BMS-986353), CD19-Targeted NEX-T CAR T Cells, in Participants with Chronic Immune Thrombocytopenia (cITP) and Autoimmune Hemolytic Anemia (AIHA) (Breakfree-AiCE)
2025-524993-41-00Chronic Immune Thrombocytopenia (cITP) and Autoimmune Hemol…
Celgene Corp.
Immune System Diseases
Germany, Denmark
10/08/2026
Phase II
An Investigator-Initiated, Descriptive, Proof-of-Concept, Open-Label Pilot Study Focusing on Topical JAK Inhibition as a Novel Treatment of Cutaneous T-Cell Lymphoma
2025-523472-23-01Cutaneous T-cell lymphoma (CTCL) Mycosis fungoides
Region Midtjylland
Therapeutics
Denmark
10/08/2026
Phase II
[22961] A placebo-controlled, parallel-group, double blind, randomized, multi-cohort Phase 2 study to investigate efficacy, safety, tolerability, pharmacodynamics and pharmacokinetics of BAY 3670549 in adult participants with atrial fibrillation.
2025-523807-31-00Atrial fibrillation
Bayer AG
Cardiovascular Diseases
Belgium, Netherlands, Germany, Poland, Italy, Hungary, Bulgaria
06/08/2026
Phase II
VIP-1 : Preclinical type 1 diabetes: the VIP-1 Study
2025-524318-27-00People with stage 1 or stage 2 T1D between the ages of 7 an…
Assistance Publique Hopitaux De Paris
Immune System Diseases
France
05/08/2026
Phase II
A Phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-finding study of YMI024 to assess efficacy in reducing inflammatory markers, safety, and tolerability in adults with stable coronary artery disease and elevated hsCRP
2026-525974-21-00Chronic Kidney Disease, Heart Failure, Coronary Artery dise…
Novartis Pharma AG
Cardiovascular Diseases
Germany
05/08/2026
Phase II
A Phase IIb Study to Evaluate the Efficacy, Safety, and Tolerability of AZD8965 in Participants with Idiopathic Pulmonary Fibrosis (IPF)) (ARGiNAUT)
2025-525016-41-00Idiopathic Pulmonary Fibrosis
AstraZeneca AB
Respiratory Tract Diseases
Poland, Hungary, Netherlands, Germany, Spain, Greece, Bulgaria, Italy, France, Denmark
04/08/2026
Phase II
Pharmacodynamic Evaluation of OV329 in Participants with Epilepsy and a Photo-Induced Generalized Epileptiform EEG-Response Phase 2 Proof-of-Concept.
2026-527114-23-00Epilepsy
Ovid Therapeutics Inc.
Nervous System Diseases
Netherlands
03/08/2026
Phase II
Botulinum toxin A in the Treatment of Chronic Postsurgical Pain in Lung Cancer Patients: A feasibility study
2026-525669-33-00Chronic postsurgical pain (CPSP)
Aalborg University Hospital
Therapeutics
Denmark
01/08/2026
Phase II
The Danish Anorexia Nervosa Psilocybin RCT (DANP-RCT). A Randomised, Active-Placebo-Controlled, Triple-blind, Superiority Study of Psilocybin-Assisted Acceptance and Commitment Therapy (ACT) in the Treatment of Treatment-resistant Anorexia Nervosa.
2025-524939-39-02Anorexia nervosa
Slagelse Hospital
Mental Disorders
Denmark
01/08/2026
Phase II
An Open-Label Phase IIa Trial Exploring the Safety, Tolerability, and Efficacy of the T Cell Engager OM336 for Desensitization of Kidney Transplant Candidates
2025-523222-40-00End stage renal failure
Medical University Of Vienna
Pathological Conditions, Signs and Symptoms
Austria
31/07/2026
Phase II
A Multicenter, Open-Label, Long-Term, Safety and Tolerability Extension Study of PTI5803 as adjunctive therapy in patients ≥ 14 years of age with drug-resistant seizures associated to focal cortical dysplasia.
2026-525161-40-00Drug resistant focal epilepsy related to focal cortical dys…
PannTheraPi
Nervous System Diseases
France
31/07/2026
Phase II
A Phase 2 Study of Alisertib in Combination with Paclitaxel in Patients with Small Cell Lung Cancer
2026-525382-47-00Small Cell Lung Cancer (SCLC)
Puma Biotechnology Inc.
Neoplasms
France, Poland, Spain
28/07/2026
Phase II
OBINUSS - Safety and efficacy of obinutuzumab in systemic sclerosis: a phase II, randomized, double-blinded versus placebo-controlled trial
2025-524003-68-00Patients with newly or active diffuse Systemic sclerosis at…
Assistance Publique Hopitaux De Paris
Immune System Diseases
France
28/07/2026
Phase II
A Cancer Research UK Phase II trial of CY-101 given via intratumoural administration in locally advanced or metastatic adrenocortical carcinoma (CLARITY)
2025-522757-19-00LOCALLY ADVANCED OR METASTATIC ADRENOCORTICAL CARCINOMA
Cancer Research UK
Neoplasms
Spain, France, Germany, Norway
27/07/2026
Phase II
A Phase 2 Study Evaluating the Safety and Efficacy of Neoadjuvant Amivantamab in Combination with Lazertinib or Chemotherapy in Resectable EGFR-Mutated Non-Small Cell Lung Cancer
2025-524816-13-00Non-small Cell Lung Cancer
Janssen Cilag International
Neoplasms
Spain
27/07/2026
Phase II
Evaluation of the effect of botulinum toxin on refractory upper limb rest tremor in parkinsonian patients, double-blind, placebo-controlled cross-over study : TOX PARK
2026-525862-23-00parkinson disease
Centre Hospitalier Universitaire De Toulouse
Nervous System Diseases
France
24/07/2026
Rows per page Showing 76–100 of 726
Previous 2 3 4 5 6 Next
Cite this view

Priya Life Science (2026). EU Clinical Trials Register (CTIS), filtered. Derived from the EMA Clinical Trials Information System. Retrieved 20 September 2026. https://priyalifescience.com/clinical-trials-europe

Query this register directly
GET /api/export.php?register=trials-eu&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Looking for Irish sites? See the Ireland, UK or USA registers. For approved medicines, see the EMA Approvals Tracker.